Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors
Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors
复制标题
DOI：
10.1001/jamaoncol.2016.2710
复制
发表时间：
2016-12-01
期刊：
影响因子：
28.4
通讯作者：
Dusetzina, Stacie B.
中科院分区：
文献类型：
--
作者：
Mitchell, Aaron P.;Basch, Ethan M.;Dusetzina, Stacie B.
重要性财务利益冲突（FCOI）的作者之间的临床实践guidelines有可能影响treatment recommendations. ObjectiveTo量化FCOI与行业作者之间的国家综合癌症网络（NCCN）guidelines.DESIGN，SETTING，AND PARTICIPANTS我们评估了FCOI发生在2014年期间在NCCN指南作者在美国。截至2014年底，所有人都是NCCN肺癌、乳腺癌、前列腺癌和结直肠癌指南委员会的医生成员。FCOI的数据来源是开放式支付，由医疗保险和医疗补助服务中心报告。这项研究是横截面。主要结果和措施的比例NCCN作者与行业的FCOI;从行业来源每个authentic.Results的平均金额收到125指南的作者，108（86%）至少有1个报告FCOI。作者平均收到10011美元（范围：0 - 106859美元）的一般性付款（GP），包括咨询，膳食，住宿和类似的价值转移，以及236066美元（范围：0 - 2756713美元）的行业研究付款（RP），包括与临床试验相关的资金。大约84%的作者接受了GP，而47%的作者接受了RP。八个（6%）的FCOI超过了50 000美元净和/或20 000美元的单一公司的最大值规定的NCCN.CONCLUSIONS和相关性NCCN指南的作者，涉及RP的FCOI是更大的价值，而那些涉及全科医生更普遍。虽然FCOI可能是由于从事重要的学术研究而产生的，但FCOI仍然可能以适得其反的方式影响指南作者。需要研究以了解如何在指南创建期间最好地管理作者FCOI。
IMPORTANCE Financial conflicts of interest (FCOIs) among authors of clinical practice guidelines have the potential to influence treatment recommendations.OBJECTIVE To quantify FCOIs with industry among authors of the National Comprehensive Cancer Network (NCCN) guidelines.DESIGN, SETTING, AND PARTICIPANTS We assessed FCOIs occurring during 2014 among NCCN guideline authors in the United States. All were physician members of the NCCN guideline committees for lung, breast, prostate, and colorectal cancer as of the end of 2014. The data source for FCOIs was Open Payments, which is publically reported by the Centers for Medicare and Medicaid Services. This study was cross-sectional.MAIN OUTCOMES AND MEASURES The proportion of NCCN authors having FCOIs with industry; the average amount received from industry sources per author.RESULTS Of 125 guideline authors, 108 (86%) had at least 1 reported FCOI. Authors received an average of $ 10 011 (range, $0-$ 106 859) in general payments (GPs), which include consulting, meals, lodging, and similar transfers of value, and $ 236 066 (range $0-$ 2 756 713) in industry research payments (RPs), including funding associated with clinical trials. Approximately 84% of authors received GPs, while 47% received RPs. Eight (6%) had FCOIs in excess of the $ 50 000 net and/or $ 20 000 single-company maximums stipulated by NCCN.CONCLUSIONS AND RELEVANCE Among NCCN guideline authors, FCOIs involving RPs were of greater value, while those involving GPs were more prevalent. Although FCOIs may result from engaging in important scholarship, FCOIs may still influence guideline authors in counterproductive ways. Research is needed to understand how best to manage author FCOIs during guideline creation.